Major trial tests drug to reverse scarring in fatty liver disease
Disease control
Ongoing
This large Phase 3 study is testing whether the drug lanifibranor can help adults with NASH, a serious form of fatty liver disease that causes inflammation and scarring. The trial involves 1,000 participants who will receive either the active drug or a placebo for 72 weeks to see…
Phase: PHASE3 • Sponsor: Inventiva Pharma • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC